The Opioid Crisis: From Morphine to Fentanyl

By the end of this module, you will be able to:

• Trace the historical evolution of the opioid crisis
• Explain the pharmacology of opioids and the role of the mu-receptor
• Recognize opioid intoxication and overdose
• Describe the mechanism and use of naloxone
• Compare harm reduction approaches to abstinence-only models
• Apply evidence-based treatment principles

Wave 1: Prescription Opioids (1990s-2010)

Key Events:

• 1990s: Pain management movement—"pain as the fifth vital sign"
• 1996: OxyContin (extended-release oxycodone) introduced
• Aggressive pharmaceutical marketing (Purdue Pharma)
• Claims of low addiction risk with "controlled release" formulations
• Prescribing rates quadrupled (1999-2010)

Consequences:

• Widespread availability of prescription opioids
• Diversion to recreational use
• Rising opioid-related deaths
• Development of new addicted populations

Wave 2: Heroin Resurgence (2010-2013)

Drivers:

• Crackdowns on "pill mills" and prescription monitoring
• Reformulation of OxyContin (abuse-deterrent)
• Prescription opioids became harder to obtain
• Heroin cheaper and more available
• Users transitioned from pills to injection

Consequences:

• Shift from pharmaceutical to illicit market
• Increased injection drug use
• Rising HIV/HCV infections
• New demographics affected (suburban, rural areas)

Wave 3: Synthetic Opioids (2014-Present)

The Fentanyl Era:

• Illicitly manufactured fentanyl enters drug supply
• 50-100x more potent than morphine
• Cheaper to produce than heroin
• Mixed into heroin, pressed into counterfeit pills
• Users often unaware of fentanyl presence

Current Statistics (approximate):

• 100,000+ drug overdose deaths annually (US)
• 70%+ involve opioids
• Fentanyl now primary driver of deaths
• India increasingly affected (pharmaceutical diversion, emerging synthetic markets)

Opioid Receptors

| Receptor | Location | Effects When Activated | |----------|----------|------------------------| | Mu (μ) | Brain, spinal cord, GI | Analgesia, euphoria, respiratory depression, constipation | | Kappa (κ) | Brain, spinal cord | Analgesia, dysphoria, sedation | | Delta (δ) | Brain | Analgesia, mood modulation |

The Mu Receptor is the primary mediator of:

• Analgesic effects (pain relief)
• Euphoria (rewarding properties)
• Respiratory depression (overdose risk)
• Physical dependence

Mechanism of Action

1. Opioid binds to mu-receptor
2. Activates inhibitory G-protein cascade
3. Reduces neuronal firing (inhibition)
4. In VTA: Disinhibits dopamine neurons → reward
5. In brainstem: Reduces respiratory drive → overdose risk
6. In spinal cord: Blocks pain signal transmission

Tolerance, Dependence, and Addiction

Tolerance:

• Develops to analgesia, euphoria, sedation
• Does NOT develop equally to respiratory depression
• This disparity increases overdose risk with escalating doses

Physical Dependence:

• Neuroadaptation to drug presence
• Withdrawal upon cessation
• Can occur with appropriate medical use

Addiction (OUD):

• Compulsive use despite harm
• Loss of control
• Behavioral/psychological component beyond physical dependence

Opioid Potency Comparison

| Opioid | Relative Potency (Morphine = 1) | Notes | |--------|--------------------------------|-------| | Codeine | 0.1 | Weak, often combined with acetaminophen | | Tramadol | 0.1-0.2 | Also affects serotonin/norepinephrine | | Morphine | 1 | Reference standard | | Oxycodone | 1.5 | Common prescription opioid | | Hydromorphone | 4 | Dilaudid | | Heroin | 2-3 | Rapidly crosses blood-brain barrier | | Fentanyl | 50-100 | Extremely potent, lipophilic | | Carfentanil | 10,000 | Veterinary use, often lethal in microgram amounts |

Recognizing Intoxication

The Opioid Triad:

1. Pinpoint pupils (miosis)
2. Respiratory depression
3. Altered consciousness (sedation to coma)

Other Signs:

• "Nodding off" (waxing and waning consciousness)
• Constipation
• Nausea
• Itching (histamine release)
• Slurred speech

Overdose Presentation

Life-Threatening Signs:

• Severe respiratory depression (< 10 breaths/min)
• Cyanosis (blue lips, fingernails)
• Unresponsive to stimulation
• Apnea (breathing stops)
• Cardiovascular collapse (late)

Risk Factors for Overdose:

• Recent abstinence (lost tolerance)
• Polydrug use (benzos, alcohol, stimulants)
• Injection route
• Using alone
• Unknown potency (fentanyl contamination)
• History of overdose
• High-dose prescription

Overdose Management

Immediate Response (Bystander):

1. Call for emergency help
2. Check responsiveness (sternal rub)
3. Administer naloxone if available
4. Rescue breathing if not breathing
5. Place in recovery position
6. Stay until help arrives

Medical Management:

• Airway, Breathing, Circulation (ABC)
• Naloxone (IV, IM, IN)
• Assisted ventilation
• Monitor for re-sedation (naloxone half-life < opioid half-life)
• Address polydrug ingestion
• Prevent aspiration

Mechanism

• Competitive antagonist at mu-opioid receptor
• Rapidly displaces opioids from receptors
• Reverses respiratory depression within minutes
• Does NOT cause respiratory depression on its own

Formulations

| Formulation | Route | Onset | Duration | Notes | |-------------|-------|-------|----------|-------| | Narcan Nasal Spray | Intranasal | 2-5 min | 30-90 min | Easy to use, community distribution | | Injectable | IM/IV/SC | 1-3 min (IV) | 30-90 min | Medical setting, faster onset IV | | Auto-injector | IM | 2-5 min | 30-90 min | Evzio (voice-guided instructions) |

Important Considerations

Re-dosing:

• May need multiple doses for fentanyl (higher potency/binding)
• Monitor for 2-4 hours (fentanyl has long duration)
• Naloxone wears off before most opioids do

Precipitated Withdrawal:

• Naloxone causes immediate withdrawal in dependent individuals
• Symptoms: Agitation, vomiting, diarrhea, pain
• Unpleasant but not life-threatening
• Patients may refuse transport due to withdrawal discomfort

Message: Do not withhold naloxone due to withdrawal concerns—saving the life is the priority.

Community Naloxone Distribution

Harm Reduction Approach:

• Naloxone kits provided to people who use drugs
• Training on recognition and administration
• "Leave-behind" programs by first responders
• Pharmacy access without prescription (many jurisdictions)

Evidence:

• Communities with naloxone distribution have reduced overdose deaths
• Cost-effective intervention
• Does not increase drug use ("moral hazard" not supported)

Philosophy

Harm reduction accepts that some drug use will occur and focuses on reducing associated harms without requiring abstinence as a precondition for services.

Key Interventions

Needle/Syringe Programs (NSPs):

• Provide sterile injection equipment
• Reduce HIV, hepatitis C transmission
• Gateway to other services (testing, treatment referral)
• Do NOT increase drug use (evidence clear)

Supervised Consumption Sites (SCS):

• Medical supervision during drug use
• Overdose reversal on-site
• Connection to services
• Reduced public drug use, public injection

Drug Checking Services:

• Test drugs for fentanyl, adulterants
• Allow informed decisions
• Detect dangerous supply contamination

Fentanyl Test Strips:

• Simple, low-cost test for fentanyl presence
• Distributed to people who use drugs
• May prompt behavior change (smaller dose, don't use alone)

Controversy and Evidence

Arguments Against:

• "Enabling" drug use
• "Sending wrong message"
• NIMBY (not in my backyard) concerns

Evidence Shows:

• No increase in drug use or initiation
• Reduced infectious disease transmission
• Reduced overdose deaths
• Increased engagement with treatment
• Cost savings to healthcare system

Timeline

Short-acting opioids (heroin, oxycodone):

• Onset: 8-12 hours after last dose
• Peak: 36-72 hours
• Duration: 5-7 days (physical symptoms)

Long-acting opioids (methadone):

• Onset: 24-48 hours after last dose
• Peak: 72-96 hours
• Duration: 10-14 days

Symptoms

Early (8-24 hours):

• Anxiety, restlessness
• Muscle aches
• Tearing, runny nose
• Sweating
• Yawning
• Insomnia

Late (24-72 hours):

• Abdominal cramping, diarrhea
• Nausea, vomiting
• Goosebumps ("cold turkey")
• Dilated pupils
• Tachycardia, hypertension

Management

Unlike alcohol/benzodiazepine withdrawal, opioid withdrawal is rarely life-threatening (except dehydration, pregnancy complications).

Symptomatic Treatment:

• Clonidine (autonomic symptoms)
• NSAIDs (muscle aches)
• Anti-diarrheals
• Anti-emetics
• Sleep aids

Medication-Assisted Treatment (preferred):

• Buprenorphine: Transition to maintenance
• Methadone: Transition to maintenance
• Prevents full withdrawal, enables stabilization

• The opioid crisis evolved through three waves: prescription opioids, heroin, and synthetic fentanyl
• The mu-opioid receptor mediates both therapeutic effects and overdose risk
• Tolerance develops to euphoria/analgesia but not equally to respiratory depression
• Naloxone is a life-saving overdose reversal agent that should be widely available
• Harm reduction approaches (NSPs, SCS, drug checking) reduce deaths without increasing use
• MAT is the gold standard for OUD, reducing mortality by 50%+
• Opioid withdrawal is uncomfortable but rarely life-threatening

Next Module: Stimulants: Cocaine, Methamphetamine & Prescription Drugs →